Rossi Daniela, Tarantino Marilù, Rossino Giacomo, Rui Marta, Juza Markus, Collina Simona
a Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section , University of Pavia , Pavia , Italy.
b Corden Pharma Switzerland LLC , Liestal , Switzerland.
Expert Opin Drug Discov. 2017 Dec;12(12):1253-1269. doi: 10.1080/17460441.2017.1383981. Epub 2017 Oct 3.
Over the last 30 years, the scientific community has directed its efforts towards the identification of enantioselective approaches to obtain the desired active enantiomer. Accordingly, efficient production of single enantiomers from small to large scale, throughout Drug Discovery (DD) programs, has become of great interest and a fundamental challenge. Areas covered: This review focuses on two fundamental strategies for preparing enantiomers in high yields and with an excellent enantiomeric excess (ee). Separation of racemates, enantioselective synthesis procedures, and integrated approaches have been extensively reviewed, to offer a guide that enables the selection of the suitable methodology for producing pure enantiomers in scales from small to large. Expert opinion: Over the past two decades, drug regulatory agencies have set strict rules on the use of racemates and pure enantiomers, leading to the transformation of the drug market. Indeed, the number of drugs approved as a single enantiomer has exponentially increased, outclassing the racemic compounds. As a consequence, the academia and pharmaceutical companies are eager to develop efficient procedures for obtaining enantiopure compounds on the desired scale.
在过去30年里,科学界一直致力于确定获得所需活性对映体的对映选择性方法。因此,在整个药物研发(DD)项目中,从小规模到大规模高效生产单一异构体已成为备受关注的重大挑战。涵盖领域:本综述聚焦于两种以高收率和优异对映体过量(ee)制备对映体的基本策略。外消旋体的拆分、对映选择性合成方法以及综合方法均已得到广泛综述,以提供一份指南,助力从小规模到大规模选择合适的方法来生产纯对映体。专家观点:在过去二十年中,药品监管机构对消旋体和纯对映体的使用制定了严格规定,这导致了药物市场的变革。事实上,被批准为单一异构体的药物数量呈指数级增长,超过了外消旋化合物。因此,学术界和制药公司都渴望开发出能按所需规模获得对映体纯化合物的高效方法。